Arbidol is a broad-spectrum antiviral compound developed in USSR in 1974. International nonproprietary name — umifenovir.
Arbidol demonstrates activity against a number of enveloped and non-enveloped viruses. It is used for the prevention and treatment of influenza and other acute respiratory viral infections in adults and children. Arbidol may also be immunomodulatory, and as such be capable of interferon induction and/or macrophage activation.
The study during the 2010-2011 influenza season in Russia provided experimental and clinical evidence of the efficacy of umifenovir against influenza viruses. The treatment of influenza-infected patients within 48 hours of symptom onset with umifenovir was associated with a significant decrease in the duration of illness (2–3 days) and symptoms (p < 0.001).
This product has not been approved by the US FDA. Arbidol has not undergone full cycle of clinical trials in the US.
Hard gelatin capsules.
Active ingredient: Umifenovir 100 mg.
Inactive ingredients: potato starch 30.14 mg, microcrystalline cellulose 55.76 mg, fumed silica 2.0 mg, povidone K 25 10.1 mg and calcium stearate 2.0 mg.
Dosage and administration
To be administered orally, before meal.
For children aged 6-12 a single dose is 100 mg (1 capsule).
For adults and children from 12 years a single dose is 200 mg (2 capsules).
Reccomendations for the treatment of ARVI and influenza: take one single dose 4 times a day (every 6 hours) for 5 days in a row.
For adults a treatment course may take 4 boxes of 10 pills x 100mg.
Hypersensitivity to umifenovir and other components of the drug, children under 6 years, pregnancy, lactation.